David Gandara, Co-Director of the Center for Experimental Therapeutics at the UC Davis Comprehensive Cancer Center, shared a post by Stephen V Liu, Director of Thoracic Oncology, Chief of the Division of Hematology and Oncology, and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, on X, adding;
“Thanks for sharing. Seems to me that in setting of EGFR mutated NSCLC transforming to SCLC that continuing OSI andstarting platinum-etoposide chemotherapy makes the most biologic sense.
Likely persistent EGFR mutated clones with propensity for brain metastases absent an EGFR TKI.”
Quoting Stephen V Liu’s post:
“Carboplatin + etoposide + durvalumab for EGFR mutant NSCLC transformed to SCLC (cohort in ORCHARD study) showed RR 43%, mDOR 4.3m, mPFS 4.2m, mOS 10.2m. Unclear contribution of immunotherapy in this setting – no clear standard (chemo-IO vs chemo-TKI).”
Title: Durvalumab plus etoposide–platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARD
Authors: Isamu Okamoto, Byoung Chul Cho, Sarah B. Goldberg, Jonathan W. Goldman, Adrianus J. de Langen, Zofia Piotrowska, Jonathan W. Riess, Helena A. Yu, M. Rosario Garcia Campelo, Jeremy Cetnar, Yu Jung Kim, Silvia Novello, Yoshimasa Shiraishi, Helen Ambrose, Paul E. Smith, Kwan Ho Tang, Jonathan M. Lehman, Xiuning Le
Other articles featuring David Gandara and Stephen V Liu on OncoDaily.